February 23, 2023 12:58 PM ESTUpdated February 24, 08:51 AM
Pharma

CMS not ready to re­con­sid­er its block on cov­er­ing new Alzheimer's drugs

Zachary Brennan

Senior Editor

The Cen­ters for Medicare and Med­ic­aid Ser­vices won’t yet re­con­sid­er a de­ci­sion that FDA-ap­proved, amy­loid-tar­get­ing mon­o­clon­al an­ti­bod­ies for Alzheimer’s dis­ease shouldn’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times